Peptide Antibiotics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Peptide Antibiotics Market is Segmented by Product Type (Ribosomal-Synthesised and Non-Ribosomal-Synthesised), Disease (Skin Infections, HABP/VABP, and More), Route of Administration (Injectable, Topical, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Peptide Antibiotics Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Peptide Antibiotics Market with other markets in Healthcare Industry

Peptide Antibiotics Market Analysis by Mordor Intelligence

The peptide antibiotics market stood at USD 5.34 billion in 2025 and is forecast to reach USD 6.83 billion by 2030, reflecting a 5.1% CAGR over the period. Rising multidrug resistance, an expanding discovery pipeline that now contains almost 900,000 AI-identified antimicrobial peptide sequences, is accelerating product innovation.[1]Sarah Dixon, “Artificial intelligence reveals 900,000 antimicrobial peptides,” nature.com Regulatory incentives such as the FDA’s Qualified Infectious Disease Product designation extend exclusivity windows and speed approvals, improving commercial viability. Meanwhile, heavy capital deployment exemplified by CordenPharma’s EUR 900 million (USD 1,043 million) manufacturing outlay and Merck’s USD 493 million oral-delivery licensing signals sustained confidence in the peptide antibiotics market. Topical hydrogel innovations and AI-guided RiPP discovery further enlarge the addressable opportunity base, even as premium pricing and production complexity temper near-term adoption.

Key Report Takeaways

  • By product type, non-ribosomal lipopeptides led with 46.1% revenue share in 2024, while ribosomal RiPPs are projected to expand at a 13.5% CAGR through 2030. 
  • By disease, skin infections accounted for 41.5% of the peptide antibiotics market size in 2024; hospital-acquired and ventilator-associated bacterial pneumonia are forecast to grow at a 10.2% CAGR to 2030. 
  • By route of administration, injectable formulations held a 70.3% share in 2024, whereas topical hydrogels are advancing at a 12.6% CAGR through 2030. 
  • By distribution channel, hospital pharmacies controlled 57.5% of 2024 revenues, and online pharmacies are expected to post a 14.4% CAGR between 2025 and 2030. 
  • By geography, North America captured 38.4% of global revenue in 2024; Asia Pacific is projected to register a 9.8% CAGR over the forecast horizon.

Segment Analysis

By Product Type: Non-Ribosomal Dominance Meets Ribosomal Innovation

Non-ribosomal lipopeptides secured 46.1% of the peptide antibiotics market share in 2024, anchored by daptomycin and polymyxins that remain indispensable against resistant Gram-positive and Gram-negative infections. Daptomycin’s ability to evade BceAB-mediated resistance in Streptococcus pneumoniae sustains its frontline status. Polymyxin B and colistin regained importance as last-resort therapies for carbapenem-resistant organisms despite emerging MCR-gene resistance. Manufacturing advances, such as CordenPharma’s plant expansions, support supply stability for this mature segment.

Ribosomal RiPPs are projected to grow at a 13.5% CAGR, the highest among product classes. Synthetic-biology tooling has uncovered 987 new RiPP gene clusters in lichen fungi, opening fresh discovery space. Machine-learning guided evolution produced LBDA-D, which shows enhanced activity against Escherichia coli and S. aureus. Heterologous expression systems now enable scalable RiPP production, reducing historical supply constraints. As a result, the peptide antibiotics market size for ribosomal candidates is set for rapid expansion over the forecast period.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Disease: Skin Infections Lead While HABP/VABP Accelerates

Skin infections accounted for 41.5% of the peptide antibiotics market size in 2024, supported by topical delivery formats that suit diabetic foot ulcers and post-surgical wounds. Locilex (pexiganan) illustrates focused development while dissolving microneedles to improve compliance in outpatient care. Long-acting lipoglycopeptides such as dalbavancin have broadened their reach beyond skin indications, reporting clinical success rates up to 100% in bloodstream infections. Growing diabetes prevalence and high rates of MRSA in community settings sustain demand for skin-directed therapeutics within the peptide antibiotics market.

Hospital-acquired and ventilator-associated bacterial pneumonia hold smaller baseline revenue but are slated for a 10.2% CAGR, the fastest among disease areas. AbbVie’s newly approved Emblaveo achieved a 76.4% cure rate in late-stage trials. Intensive-care infection rates remain high, with S. maltophilia doubling in incidence over two decades. The critical nature of respiratory infections ensures premium reimbursement and steady hospital uptake, and advanced inhalable or long-acting injectable peptides under development promise to deepen future penetration.

By Route of Administration: Injectable Dominance Challenged by Topical Innovation

Injectables maintained a 70.3% revenue share in 2024, underscoring the necessity for rapid systemic exposure in severe infections. Vancomycin achieved appropriate use in 89.1% of cardiac-surgery cases following IDSA protocols. Cold-chain infrastructure and trained infusion staff favour hospital settings, keeping the peptide antibiotics market anchored in inpatient care. However, high production costs and lengthy infusion times present cost-containment challenges for payers.

Topical hydrogels, rising at a 12.6% CAGR, employ self-assembling peptide networks that achieve minimum inhibitory concentrations as low as 2 µM against MRSA. Hydrogel microspheres now pack high drug loads with controlled release, solving earlier capacity issues. Patient preference for non-invasive therapy and the reduced risk of systemic toxicity fuel adoption. The peptide antibiotics market, therefore, shows growing modality diversification beyond traditional intravenous regimens.

Peptide Antibiotics Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Hospital Pharmacy Control Meets Online Growth

Hospital pharmacies controlled 57.5% of global sales in 2024 due to the acute nature of infections addressed and the sterility requirements of many formulations. Centralized compounding units and temperature-controlled storage preserve drug integrity, reinforcing hospital leadership. The prevalence of healthcare-associated infections, estimated to affect millions annually, keeps peptide antibiotic demand concentrated in inpatient care.

Online pharmacies, forecast at a 14.4% CAGR, benefit from telehealth expansion and the advancing feasibility of oral peptide delivery. Merck’s USD 493 million Cyprumed deal aims to transform peptides into tablets, a development that would expand outpatient channels. Retail pharmacies occupy a middle ground, dispensing oral agents and select topical products, but growth remains limited until more peptide antibiotics transition to community prescribing.

Geography Analysis

North America generated 38.4% of 2024 global revenue, the highest regional contribution. The FDA’s QIDP framework expedited approvals for cutting-edge agents such as Blujepa and Emblaveo, while BARDA committed USD 318 million in contracts to antimicrobial R&D. Private investments, including Eli Lilly’s USD 100 million AMR fund and CordenPharma’s plant expansion, reinforce supply and discovery capacity. Research hubs like McMaster University continue to pioneer AI-based discovery models, expanding the peptide antibiotics market footprint across North America.

Asia Pacific is the fastest-growing region with a projected 9.8% CAGR through 2030. AstraZeneca’s USD 2.5 billion Beijing R&D center enhances local peptide capabilities, while Chinese regulators approved Vibativ for serious infections, giving Cumberland Pharmaceuticals access to a vast market. Singapore’s institutes are advancing bacteriophage-peptide synergy programs, underscoring region-wide commitment to antimicrobial resistance. Government stewardship initiatives, coupled with capacity additions across India and South Korea, drive sustained uptake within the peptide antibiotics market.

Europe remains a pivotal contributor, supported by EMA streamlined pathways and manufacturing depth. Positive CHMP opinion for Pfizer’s aztreonam-avibactam highlights regulatory efficiency. Academic centres such as Chalmers University developed peptide hydrogels that boost oxacillin potency 64-fold, demonstrating innovation strength. Meanwhile, Middle East and Africa and South America show nascent adoption, aided by improving healthcare infrastructure and awareness campaigns focused on antimicrobial stewardship.. At the same time,the region's,,,the . At the same time,   

Peptide Antibiotics Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The peptide antibiotics market features moderate concentration, with leading firms leveraging scale, AI partnerships, and manufacturing depth to secure advantage. Merck’s USD 493 million Cyprumed deal aims to overcome oral-delivery barriers that have long constrained peptide uptake. 

Strategic alliances increasingly center on AI-driven discovery; Eli Lilly’s partnership with OpenAI exemplifies how generative models can compress hit-to-lead timelines. At the device interface, Amferia’s EUR 1.2 million (USD 1.3 million) investment positions its hydrogel dressings for rapid U.S. entry, achieving 64-fold potency improvements over standard care. White-space opportunities in long-acting injectables encourage players such as Melinta to invest in weekly-dosed lipoglycopeptides, extending hospital discharge options.

Emerging disruptors include Peptilogics, which secured CARB-X funding for fracture-infection therapeutics, and startups leveraging synthetic biology to create bespoke RiPPs. Competitive tactics also involve aggressively pursuing QIDP status to gain five additional years of exclusivity and access to priority FDA review queues. Overall, investment scale and regulatory expertise remain decisive factors shaping positioning within the peptide antibiotics market.

Peptide Antibiotics Industry Leaders

  1. Merck & Co., Inc.

  2. ANI Pharmaceuticals, Inc.

  3. Melinta Therapeutics.

  4. AbbVie

  5. Cumberland Pharmaceuticals Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Screenshot 2022-12-09 132256.png
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: GSK received FDA approval for Blujepa (gepotidacin), the first triazaacenaphthylene bacterial topoisomerase inhibitor for uncomplicated urinary tract infections.
  • March 2025: AstraZeneca announced a USD 2.5 billion R&D center in Beijing with macro-cyclic peptide collaborations.
  • February 2025: AbbVie obtained FDA clearance for Emblaveo (aztreonam-avibactam) to treat multidrug-resistant Gram-negative infections.
  • February 2025: Cumberland Pharmaceuticals gained Chinese approval for Vibativ (telavancin) in pneumonia and severe skin infections.

Table of Contents for Peptide Antibiotics Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence Of Multidrug-Resistant Bacterial Infections
    • 4.2.2 Intensifying R&D Pipeline For Ribosomal & Non-Ribosomal Peptide Antibiotics
    • 4.2.3 Favourable Regulatory Incentives (GAIN/QIDP, Orphan Status)
    • 4.2.4 AI-Driven Genome-Mining Unlocking Novel RiPP Classes
    • 4.2.5 Peptide-Hydrogel Delivery Platforms Expanding Topical & Implant Use-Cases
    • 4.2.6 Surging Demand For Last-Resort Antibiotics In Critical Care Settings
  • 4.3 Market Restraints
    • 4.3.1 High Production Costs & Premium Pricing
    • 4.3.2 Cytotoxicity & Stability Challenges In Systemic Applications
    • 4.3.3 Limited Reimbursement And Pricing Incentives For Novel Antibiotics
    • 4.3.4 Stringent Regulatory Requirements For Demonstrating Superiority Over Existing Therapies
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product Type
    • 5.1.1 Ribosomal-synthesised peptide antibiotics
    • 5.1.2 Non-ribosomal-synthesised peptide antibiotics
  • 5.2 By Disease
    • 5.2.1 Skin infection
    • 5.2.2 HABP / VABP
    • 5.2.3 Blood-stream infection
    • 5.2.4 Other infections
  • 5.3 By Route of Administration
    • 5.3.1 Injectable
    • 5.3.2 Topical
    • 5.3.3 Others
  • 5.4 By Distribution Channel
    • 5.4.1 Hospital pharmacies
    • 5.4.2 Retail pharmacies
    • 5.4.3 Online pharmacies
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes global overview, market-level overview, core segments, financials as available, strategic information, market rank/share, products & services, recent developments)
    • 6.3.1 Merck & Co.
    • 6.3.2 GSK plc
    • 6.3.3 Melinta Therapeutics
    • 6.3.4 AbbVie
    • 6.3.5 Xellia Pharmaceuticals
    • 6.3.6 Sandoz AG
    • 6.3.7 Cumberland Pharmaceuticals
    • 6.3.8 Pfizer Inc.
    • 6.3.9 Eli Lilly & Co.
    • 6.3.10 Amferia AB
    • 6.3.11 AstraZeneca plc
    • 6.3.12 CordenPharma International
    • 6.3.13 Thermo Fisher Scientific
    • 6.3.14 Teva Pharmaceuticals
    • 6.3.15 Zhejiang Hisun Pharma
    • 6.3.16 Lupin Ltd
    • 6.3.17 Glenmark Pharmaceuticals

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Peptide Antibiotics Market Report Scope

As per the scope of the report, peptide antibiotic products are commonly used in the management of various infectious diseases. These antibiotics are less toxic and highly effective as compared to the other antibiotics. The peptide antibiotics market is segmented by Product Type (Ribosomal Synthesized Peptide Antibiotics and Non-Ribosomal Synthesized Peptide Antibiotics), Disease (Skin Infection, HABP/VABP, Blood Stream Infection, and Others), Route of Administration (Injectable, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product Type Ribosomal-synthesised peptide antibiotics
Non-ribosomal-synthesised peptide antibiotics
By Disease Skin infection
HABP / VABP
Blood-stream infection
Other infections
By Route of Administration Injectable
Topical
Others
By Distribution Channel Hospital pharmacies
Retail pharmacies
Online pharmacies
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
South Korea
Australia
Rest of Asia Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Ribosomal-synthesised peptide antibiotics
Non-ribosomal-synthesised peptide antibiotics
By Disease
Skin infection
HABP / VABP
Blood-stream infection
Other infections
By Route of Administration
Injectable
Topical
Others
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
South Korea
Australia
Rest of Asia Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the peptide antibiotics market?

The market generated USD 5.34 billion in 2025 and is on track to reach USD 6.83 billion by 2030.

Which product category holds the largest peptide antibiotics market share?

Non-ribosomal lipopeptides led with 46.1% revenue share in 2024.

Which route of administration is growing fastest for peptide antibiotics?

Topical hydrogels are projected to grow at a 12.6% CAGR through 2030 thanks to advanced peptide-hydrogel platforms.

Why is Asia Pacific considered the fastest-growing region?

Significant healthcare investment, regulatory progress and rising antimicrobial resistance awareness drive a forecast 9.8% CAGR in Asia Pacific.

How do regulatory incentives support peptide antibiotic development?

Programs such as the FDA’s QIDP grant five extra years of exclusivity and priority review, accelerating approvals and improving commercial viability.

What are the main challenges limiting broader peptide antibiotic use?

High manufacturing costs, premium pricing, and stability issues in systemic applications remain key restraints.

Page last updated on: June 24, 2025

Peptide Antibiotics Market Report Snapshots